Legal & General Group
ENTA icon

Legal & General Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Legal & General Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.8K Hold
2,438
– – ﹤0.01% 2829
2025
Q4 		$38.4K Buy
2,438
+734
+43% +$9.32K ﹤0.01% 2797
2025
Q3 		$20.4K Sell
1,704
-264
-13% -$2.11K ﹤0.01% 3025
2025
Q2 		$14.9K Hold
1,968
– – ﹤0.01% 3134
2025
Q1 		$10.9K Hold
1,968
– – ﹤0.01% 3148
2024
Q4 		$11.3K Hold
1,968
– – ﹤0.01% 3229
2024
Q3 		$20.4K Buy
1,968
+279
+17% +$3.65K ﹤0.01% 3043
2024
Q2 		$21.9K Sell
1,689
-53
-3% -$715 ﹤0.01% 2987
2024
Q1 		$30.4K Sell
1,742
-956
-35% -$12.7K ﹤0.01% 2853
2023
Q4 		$25.4K Sell
2,698
-9,641
-78% -$89.8K ﹤0.01% 2938
2023
Q3 		$138K Sell
12,339
-42,748
-78% -$688K ﹤0.01% 2793
2023
Q2 		$1.18M Sell
55,087
-955
-2% -$28.2K ﹤0.01% 2155
2023
Q1 		$2.27M Sell
56,042
-340
-0.6% -$16.2K ﹤0.01% 1832
2022
Q4 		$2.62M Buy
56,382
+1,404
+3% +$64K ﹤0.01% 1745
2022
Q3 		$2.85M Sell
54,978
-273
-0.5% -$15.9K ﹤0.01% 1671
2022
Q2 		$2.61M Buy
55,251
+69
+0.1% +$3.75K ﹤0.01% 1743
2022
Q1 		$3.93M Buy
55,182
+16
+0% +$1.04K ﹤0.01% 1660
2021
Q4 		$4.13M Buy
55,166
+4,812
+10% +$378K ﹤0.01% 1679
2021
Q3 		$2.86M Buy
50,354
+3,763
+8% +$186K ﹤0.01% 1855
2021
Q2 		$2.05M Sell
46,591
-12,178
-21% -$596K ﹤0.01% 1965
2021
Q1 		$2.9M Buy
58,769
+829
+1% +$41.4K ﹤0.01% 1814
2020
Q4 		$2.44M Buy
57,940
+112
+0.2% +$4.93K ﹤0.01% 1805
2020
Q3 		$2.65M Buy
57,828
+4,347
+8% +$211K ﹤0.01% 1648
2020
Q2 		$2.69M Buy
53,481
+2,211
+4% +$114K ﹤0.01% 1605
2020
Q1 		$2.64M Buy
51,270
+4,525
+10% +$241K ﹤0.01% 1459
2019
Q4 		$2.89M Buy
46,745
+3,019
+7% +$187K ﹤0.01% 1620
2019
Q3 		$2.63M Buy
43,726
+2,177
+5% +$162K ﹤0.01% 1597
2019
Q2 		$3.51M Buy
41,549
+355
+0.9% +$31.9K ﹤0.01% 1449
2019
Q1 		$3.94M Buy
41,194
+3,768
+10% +$338K ﹤0.01% 1347
2018
Q4 		$2.64M Buy
37,426
+11
+0% +$843 ﹤0.01% 1446
2018
Q3 		$3.23M Buy
37,415
+8,465
+29% +$848K ﹤0.01% 1458
2018
Q2 		$3.32M Buy
28,950
+1,886
+7% +$188K ﹤0.01% 1374
2018
Q1 		$2.17M Buy
27,064
+805
+3% +$62K ﹤0.01% 1580
2017
Q4 		$1.54M Buy
26,259
+217
+0.8% +$10.9K ﹤0.01% 1720
2017
Q3 		$1.22M Buy
26,042
+876
+3% +$35.2K ﹤0.01% 1781
2017
Q2 		$906K Buy
25,166
+2,080
+9% +$66.5K ﹤0.01% 1860
2017
Q1 		$711K Sell
23,086
-633
-3% -$19.7K ﹤0.01% 1921
2016
Q4 		$795K Buy
23,719
+11,310
+91% +$324K ﹤0.01% 1836
2016
Q3 		$330K Buy
12,409
+9,643
+349% +$224K ﹤0.01% 1883
2016
Q2 		$60K Hold
2,766
– – ﹤0.01% 2373
2016
Q1 		$82K Buy
2,766
+776
+39% +$21.6K ﹤0.01% 2174
2015
Q4 		$66K Hold
1,990
– – ﹤0.01% 2309
2015
Q3 		$69K Hold
1,990
– – ﹤0.01% 2261
2015
Q2 		$88K Hold
1,990
– – ﹤0.01% 2208
2015
Q1 		$62K Hold
1,990
– – ﹤0.01% 2374
2014
Q4 		$101K Hold
1,990
– – ﹤0.01% 1959
2014
Q3 		$79K Buy
+1,990
New +$79.3K ﹤0.01% 2067

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Legal & General Group's ENTA Position: Q1 2026 in Review

Legal & General Group held its Enanta Pharmaceuticals (ENTA) position steady in Q1 2026 at 2,438 shares worth $30.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2829.

Legal & General Group first reported a position in ENTA in Q3 2014 and has held it in 47 quarters since. The position peaked at $4.13M in Q4 2021. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Legal & General Group held 2,438 shares of Enanta Pharmaceuticals worth $30.8K as of Q1 2026.
  • Legal & General Group left its Enanta Pharmaceuticals share count unchanged in Q1 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2829 holding.
  • Legal & General Group first reported a position in Enanta Pharmaceuticals in Q3 2014 and has held it in 47 quarters since.
  • Legal & General Group's Enanta Pharmaceuticals position peaked at $4.13M in Q4 2021.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.